Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's see who makes the next move, there is no way JAGX doesn't know they're being shorted. It's all about timing and facts, everything else is just noise.
Those borrow fees have been 60% for days and they barely moved the price...
When JAGX had it's highest volume day EVER of 650,000,000 , there was over 298,000,000 dark pool short volume. Unfathomable numbers to think about.
Over the past 30 days, the average Off Exchange & Dark Pool volume has been 60.28%.
Timberwolf, I've looked at as much short interest and dark pool short volume as is available. My guess of how much money the shorts are down, translates to a marketcap well past the $1 mark. And that's just for them to break even. IMHO this is not financial advice to anyone here, I've done over 100 hours of research.
REASONABLE MARKET CAP guesses??
Current market cap around $48 Mil... Goes to 50 cents and they have a market cap of $143 Million..
Be nice to see them talk about the potential 'revenue' stream off the licensing deal, give some insight into what they see happening.
Happy adding day ..
Not much,out of powder.
Accumulating Time! Breakout Any Moment! News will come of the Conference this week and or Something Else i predict.
Correct , thankyou
If you look at the month chart you can see possibly the most beautiful bull flag I've ever witnessed, with the bollinger bands tightly closing. I'm in love lol xD
The silence is everything ;)
Tell you go to abga, 50cent spread
super pumpers😉 great day trade
make jus très heureux !
Fighting back today...
Check BLIS by the way jus, great chart play.
That $ 75mil dilution must be in play today....watch for filing out....no way in .19 this morning and go .16 red now
Golden cross has occured at .17 , SMA 200 and SMA 50 have now crossed, this could get interesting :)
LEVEL 2 ACTIVITY DEAD ALL EYES GLUED TO WEBSITE FOR ABSTRACT TITLE MENTION OR ANYTHING RELATED TO NAPO
ITS COMING ONLY A MATTER OF TIME THE SHIT IS DUE TODAY
I REPEAT, NOT EVERYTHING HAS BEEN UPDATED AS OF YET
DONT PANIC
APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org
NOT ALL THINGS HAVE BEEN UPDATED AS OF 9;28AM
Did Jaguar posted anything on ASCO website...
DONT PANIC
APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org
APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org
APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org
0 SHARE AVAIL TO SHORT, 60% FEE ABSTRACT TITLES POSTED IN T MINUS 38 MINUTES... TIK TOK TIK TOK
DATES TO KNOW
APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org
APRIL 24, 2024
Early Registration Deadline
MAY 13, 2024
Oral Abstract presentation slide deadline. Materials must be uploaded to ASCO's Speaker Center Website
MAY 20, 2024
Poster and Rapid Oral Abstract presentation presentation materials (slides and/or posters). Materials must be uploaded to ASCO's Speaker Center Website
MAY 23, 2024 at 5PM et
Majority of abstracts are released on asco.org/abstracts (Late-breaking Abstracts will be released at 7:00 AM CT on their day of presentation at the meeting)
MAY 31 - JUNE 4, 2024
ASCO Annual Meeting (Chicago, IL)
Damn I wish I had a buy order set when it zoomed down to .11s the other evening.
I kinda understand your point here. It's a situation of why? I don't have time to DD Jaguar thoroughly. I have been day trading for about 20 years. Option, future, penny stocks, SPY, QQQ, NVDA, META and believe it or not CMKX. for this one I'll hold (don't do it coz of I do). I held $ZOM and it paid off nicely. For Jaguar I'll roll the dice. GLTA. PEACE
P.S for entertaining purpose only, I'm betting that market will ends up READ on THURSDAY close. Have a good market.
If it breaks the 38.2% fib support lvl today, we could have some serious attention on JAGX in the market.
With Conference This Week! This could have Significant Gains by End of Week!
Extremely low volume however it broke the first support Fibonacci support lvl. Let's see if the German market responds
Really low volume today
Needless to say it merely cannot exceed $75 million with no timeframe…. Could be $20 mill or $50 mill who knows and the best thing its not just what your insinuation of all being comman shares.they mentioned other avenues such as preferred shares….
SITTING HERE LOOKING AT THE 5 DAY...1 AND 3 MONTH CHART ON JAGX AND I DONT THINK YOU CAN FIND ANY SWEETER!!...SHE GOT STRONGER ALL DAY TODAY...GOTTA REAL GOOD FEELING ABOUT TOMORROW......JAGX DUE A HUGE MONSTROUS BREAKOUT ANYTIME AND THE COMPANY SEEMS TO KNOW ITS COMING...GLTA JAGX PEEPS!!!!!!$$$$$$$
I'll be up at 4am tomorrow so if I catch wind of any news drop I'll post for everyone :D
Nice recovery from last evenings AHs drop to .11
People are missing key facts here, the Napo pharmas abstract gets either accepted tomorrow or not for the presentation at it's booth for the conference in June. They already have a booth#, this is their first time presenting, they will be presenting near ImmunityBio, and among top billion dollar companies. look it up on my previous posts. Accepted means good news, they are going either way they have a BOOTH#. Do you think company wants to present TOPLINE PH3 data in June with a stock price under $1? THINK!!!!!! 🧐🧐
Gap fill .26 then 50s then $1 this stock is going to fly
A company that is suffering might do that. That is not the case here. Shelf will be used for funding FDA timeline, shelf will not be used like your negativity suggests
well recognized the RETAIL sector is not likely to move a stocks share price on their own.. That for it to happen in earnest, the bigger players on Wall Street NEED to be involved.
Why tho they tabled the r/split, couple that with the pending PH 3 PR, couple that with the announcement of authorizing up to $75 Mil in share sales??
You have to assume the company knows they need to move the share price up to around $4-5 so that the street can start to ''participate'..
Still have to hope the retail sector can move this up to say 50 cents first. Cut down the darn size of the r/split..
You could literally throw yesterdays trading Action out the window that was a doozy. Wow I've never seen such a dump then escalate move like with today's action. Know what you own. I'm not selling all my shares on initial pump,holding half more than a year. After FDA approval this goes $25+, r/s will not be needed, the shelf offering yesterday will fund the rest of they way.
in the meantime this will pump and dump over a $1 after ph3 data, it might even go $5+ and stay there like ImmunityBio, which is another company presenting at the conference right next to us.
Play it smart boys.
Strong bullish sign
Oui
You and day traitor amis dump on good people, mess up stock
Go to abga, bon trading there
Followers
|
149
|
Posters
|
|
Posts (Today)
|
6
|
Posts (Total)
|
5953
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |